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Histone demethylasesPlant homeodomain (PHD) finger containing proteins are important epigenetic regulators and are of
interest as potential drug targets. Inspired by the amiodarone derivatives reported to inhibit the PHD
finger 3 of KDM5A (KDM5A(PHD3)), a set of compounds were synthesised. Amiodarone and its
derivatives were observed to weakly disrupt the interactions of a histone H3K4me3 peptide with
KDM5A(PHD3). Selected amiodarone derivatives inhibited catalysis of KDM5A, but in a PHD-finger
independent manner. Amiodarone derivatives also bind to H3K4me3-binding PHD-fingers from the
KDM7 subfamily. Further work is required to develop potent and selective PHD finger inhibitors.
 2018 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
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Most human genes are subject to epigenetic regulation, includ-
ing by the post-translational modifications of histones. These ‘epi-genetic marks’ are recognised and maintained by a diverse set of
regulatory proteins and enzymes.1 The maintenance of these
marks is vital for the functioning and maintenance of cells, and
their dysregulation is linked to multiple diseases, including cancer,
cardiovascular disease, and developmental disorders.2–5
Plant homeodomain (PHD) fingers are C4HC3 type zinc-finger
binding domains present in many chromatin-modifying pro-
teins.6,7 These small 50–10033 residue domains bind to histones
to enable the localisation of enzyme(s) to specific targets and
Fig. 1. PHD-finger domains associated with the JmjC-KDMs. A) Phylogenetic tree of the PHD-finger domains in human JmjC-KDM family proteins. Branch lengths are
indicated as a cladogram, and recognized histone marks in green. B) Domain architectures of selected JmjC-KDMs with PHD-fingers.
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associated protein complexes.7 While the roles of many PHD-
fingers are unclear, some PHD-fingers recognise specific histone
modifications, including non-methylated or methylated lysines
(e.g., histone H3 at K4 and K9), arginines (e.g., H3R2me1/me2),
and acetylated lysines (e.g., H3K14).7,8 PHD-fingers can also func-
tion as allosteric modulators of the activities of associated
enzymes. Mutations, deletions or chromosomal translocations of
PHD-finger encoding genes are linked to a range of diseases,
including cancer, immunodeficiency and neurological disorders;6,7
thus PHD-fingers are important epigenetic regulators.
Histone modifying enzymes, such as in the Jumonji-C (JmjC)
domain-containing histone lysine demethylases (JmjC-KDMs),
sometimes contain multiple PHD-fingers (Fig. 1).9 The KDM5 sub-
family of JmjC-KDMs (KDM5A-D) catalyses demethylation of the
transcriptionally activating tri- and di-methylated lysine-4 mark
on histone H3 (H3K4me3/2), and is generally associated with
transcriptional repression.10–13 The KDM5s are associated with
development and progression of multiple cancers,11,14 and can
mediate cancer cell drug tolerance and maintain tumour-initiating
cells.15,16 KDM5A/B have three PHD-fingers (PHD1-3, numbered
sequentially from the N-terminus), whereas KDM5C/D have two.
The roles of KDM5 PHD-fingers are partially characterised:
KDM5A/B(PHD3) binds to H3K4me3, with decreasing affinity for
lower methylation states,17 whereas KDM5A/B(PHD1) recognizes
H3K4me017 (demethylation product), and is implicated in
‘allosteric’ activation of KDM5 catalysis.18 It is proposed that
PHD3 of KDM5A/B directs the JmjC domain to the H3K4me3 site;
PHD1 binds to the demethylated product H3K4me0 and activates
the JmjC domain through a positive-feedback mechanism. This is
thought to propagate the transcriptionally inactive state of chro-
matin by K4me3 removal along the H3K4me3-enriched promot-
ers.17,18 KDM5A(PHD3) is implicated in acute myeloid leukemia
(AML) and forms a fusion protein with nucleoporin protein 98
(NUP98), a common translocation partner.19 This fused KDM5A
(PHD3):NUP98 found in AML patients directs the ‘‘oncoprotein”
to H3K4me3 promoter sites, inducing aberrant active transcription
leading to AML, as shown in cellular and animal models.20 PHD3
mutations that disrupt H3K4me3 binding inhibit leukaemic trans-
formation.20 In ER- breast cancers, KDM5A promotes progression
and metastasis, but its critical role in metastasis is apparently inde-
pendent of its catalytic activity and regulated by the N-terminal
PHD1/ARID domain regions.21 A point mutation (A388P) in
KDM5C(PHD1) is linked to patients with X-linked mentalretardation, and manifests reduced H3K4 demethylase activity.13
Overall, these results identify their PHD-finger domains to be
crucial to the KDM5 function(s) (both catalytic and non-catalytic),
and in addition to JmjC-targeting,22,23 suggest they are interesting
targets for oncology.
By contrast to the catalytic domains of epigenetic proteins, (e.g.,
DNA methyltransferases, histone deacetylases, histone methyl-
transferases, demethylases and bromodomains),24,25 chemical
tools for PHD-fingers are lacking and progress towards inhibitor
development has been limited.26,27 PHD-finger inhibitors will be
useful in exploring their biological functions and therapeutic
potential.
In 2012, Wagner et al. identified amiodarone (AMI), an antiar-
rhythmic drug, as an inhibitor of KDM5A(PHD3).26 Analogues of
AMI (WAG-003, WAG-005) were reported to inhibit the binding
of KDM5A(PHD3) to H3K4me3 with IC50 values of 30 ± 14 mM
and 41 ± 16 mM, respectively, on the basis of a HaloTag-based pep-
tide displacement assay, and supported by fluorescence polarisa-
tion assay results.26 While WAG-003 also inhibited other
H3K4me3 binding domains (PHD in RAG and double tudor domain
(DTD) in KDM4A), it showed modest selectivity over other tested
PHD-fingers and Tudor domains (AIRE PHD1, BHC80 PHD, UHRF1
(TDD)). However, the mode of action of AMI derivatives and their
potential effect on KDM5A catalytic activity was unclear.
We describe the synthesis of a series of AMI derivatives and
structure-activity-relationship (SAR) studies on their KDM5A
(PHD3) binding and H3K4me3 demethylation catalysis by KDM5A
(Fig. 2). The results reveal that, while AMI and its derivatives bind
weakly to PHD-fingers of KDM5A and other PHD-fingers within the
JmjC-KDMs, they also inhibit the demethylation activity in a PHD-
finger independent manner, suggesting AMI derivatives can act via
more than one binding mode.
2. Results
2.1. Synthesis of AMI derivatives
The AMI derivatives were synthesised as in Scheme 1. To
explore the importance of alkylation at the 20-position of the ben-
zofuran core, benzofuran derivatives 3 were reacted with 4-
methoxybenzoyl chloride 4 using AlCl3 mediated Friedel-Crafts
acylation to give 5a–d. AlCl3-mediated demethylation yielded
6a–d; alkylation of the phenol of these with N,N-dimethyl-3-
chloropropylamine afforded dimethylated lysine analogues 1a–d.
Fig. 2. Design of potential PHD-finger binders from the structure of amiodarone.
Scheme 1. Synthesis of derivatives of 1a.
2986 B. Bhushan et al. / Bioorganic & Medicinal Chemistry 26 (2018) 2984–2991Treatment with iodomethane gave the corresponding quaternary
ammonium compounds 2a–d. For diversification at the aryl por-
tion of AMI, 3a and 3b (Scheme 1b) were employed. 3,4,5-
Trimethoxybenzoyl chloride and 3,5-difluoro-4-methoxybenzoyl
chloride were used to prepare 8a and 8b respectively. 2-Methoxy-
benzoyl chloride was used to prepare 7a and 7b, the regioisomers
of 2a and 2b, respectively, to investigate the effect of altering the
position of the 3-(trimethylammino)-propoxy group from the
para- to the ortho-position.
To explore the importance of the quaternary ammonium of his-
tone lysines for binding to KDM5A(PHD3), different alkylated ami-
nes of AMI were prepared, starting from 6a (Scheme 2). Thus,
alkylation of 6a gave 9, which was deprotected to give primary
amine 10. Mitsunobu reaction of 6a with N,N-diethyl-3-amino-
propanol gave 11 in moderate yield, which was converted to 12
by reaction with iodoethane.342.2. Development of KDM5A(PHD3) AlphaScreen binding assay
To assess whether the AMI derivatives inhibit binding of histone
H3K4me3 peptide to KDM5A(PHD3), we developed an AlphaScreen
displacement assay. AlphaScreen is a homogenous bead-based
assay used to study protein-protein interactions.28 We used a
streptavidin-conjugated donor and nickel-conjugated acceptor
bead pair to detect the interactions of His6-tagged KDM5A(PHD3)
(His-KDM5A(PHD3)) and C-terminally biotinylated-H3(1–21)
K4me3 (H3K4me3-Bn) (Fig. 3A). Optimised assay conditions were
determined to ensure that the His-KDM5A(PHD3) and H3K4me3-
Bn interactions could be detected in the linear range of the assay,
with good signal-to-background ratio (Supplementary Fig. S1). To
investigate the inhibition of the protein-peptide interaction,
His-KDM5A(PHD3) was pre-incubated with compounds (15 min),
followed by incubation with H3K4me3-biotin (30 min). AlphaSc-
reen beads were then added and incubated for 1 h. Changes in
Fig. 3. Screening of AMI analogues for binding and catalytic inhibition of KDM5A. (A) AlphaScreen assay for H3K4me3 and His-KDM5A(PHD3) interactions. (B) Normalised
dose–response inhibition curves for displacement of H3K4me3-Bn from KDM5A(PHD3) by representative AMI derivatives. Average ± StdDev (N  3 independent replicates).
(C, D) Dose-response inhibition curves of H3K4me3 demethylation activity by AMI derivatives for KDM5A using a MALDI-TOF MS-based assay. AMI derivatives were tested
against two active KDM5A constructs, KDM5A_c1 (M1-L801), and KDM5A_c2 (DARID/PHD1, L88-G353). KDOAM25a is a small molecule JmjC-domain inhibitor of KDM5.
Scheme 2. Modification of the quaternary ammonium group of potential PHD inhibitors.
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were then measured to quantify the level of KDM5A(PHD3) and
H3K4me3 binding, and IC50 values were determined. Using this
setup, IC50 values for displacement of biotinylated H3K4me3 by
non-biotinylated histone peptides were seen to decrease with
increasing methylation state at H3K4 (Kme3 < Kme2 < Kme1 <
Kme0) (Supplementary Fig. S2) confirming the rank order of pep-
tide affinities to KDM5A(PHD3), as previously reported based on
isothermal titration calorimetry.20 Following assay optimisation,
the set of AMI derivatives was tested for KDM5A (PHD3) inhibitory
activity (Table 1, Fig. 3B, Supplementary Fig. S3).
Interestingly, although the AlphaScreen-based peptide dis-
placement assay works on similar principles to the HaloTag assay
reported by Wagner et al.,26 IC50 values measured againstKDM5A(PHD3) differed for the set of AMI derivatives in our assays.
Whilst WAG-005 and WAG-003 are reported to have IC50 values of
30–40 mM using the Halo-tag assay, they had >10-fold (562 mM)
and >50-fold higher IC50 values (1658 mM), respectively, in our
assay. While AMI had an IC50 value of 99 mM, non-specific interfer-
ence of AMI (and some derivatives) with the AlphaScreen assay in
the counter screen using biotin-His6 was observed (Table 1). Tak-
ing this into account, SAR analysis of further AMI variants on
KDM5A(PHD3) indicates that removal of the 3,5-di-iodo
substitutions from the WAG-005 aryl group increased potency
(2a, IC50 = 340 mM); alternative substitutions (3,5-dimethoxy (8a),
3,5-difluoro (8b)) were also favourable (198 mM, 223 mM respec-
tively). The results reveal that p-substitution (2a) is favoured over
o-substitution (7a) for the 3-(trimethylammino)-propoxy group.
Table 1
AMI derivatives (Fig. 2) and associated Alphascreen IC50 values for displacement of H3K4me3-Bn from His-KDM5A(PHD3). Average ± StdDev (n  3 independent replicates)
shown. H3(1–21)K4me3 IC50: 218 ± 16 nM.
Compounds A R1 R2 R3 = R5 R4 IC50 (mM) Biotin-His6
counterscreen
Amiodarone
(AMI)
O butyl H I 99 ± 23 178 ± 58
WAG-003 O butyl H I 1658 ± 490 11280 ± 1258
WAG-005 O butyl H I 562 ± 130 2584 ± 127
1a O butyl H H 166 ± 20 484 ± 82
2a O butyl H H 340 ± 44 4297 ± 163
2b O methyl H H 844 ± 23 6291 ± 1865
2c S methyl H H 533 ± 109 805 ± 55
2d NMe H H H 1310 ± 39 970 ± 60
7a O butyl H H 1146 ± 100 DNCa
7b O methyl H H 2305 ± 82 DNCa
8a O butyl H OMe 223 ± 60 309 ± 70
8b O butyl H F 198 ± 50 455 ± 57
9 O butyl H H NMb NMb
10 O butyl H H 198 ± 41 376 ± 69
12 O butyl H H 314 ± 30 1335 ± 326
a DNC: data did not converge to binding model.
b NM: not measurable within the solubility range of the compound. Final concentration of protein and peptide were 25 nM.
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tiary amine (di-methyl (1a)) was the most potent inhibitor with
an IC50 value of 166 mM, followed by the primary amine (10), with
the quaternary amine (tri-methyl- (2a), tri-ethyl (12)) being least
potent. Reducing the length of the alkyl chain at R1 from butyl
(2a) to methyl led to a reduction in activity (2b). The benzophe-
none 2c was more potent than 2b for KDM5A(PHD3), whilst the
N-methylindole analogue (2d) had reduced activity. These studies
suggest that further exploration and diversification of the hetero-
cyclic rings is of interest. Overall, the most potent inhibitor in this
panel against KDM5A(PHD3) was 1a with an IC50 of 166 mM.
2.3. Inhibition of KDM5A demethylation activity by AMI derivatives
We next investigated the effect of AMI derivatives on the
demethylation activity of KDM5A. Two catalytically active con-
structs of KDM5A were employed, KDM5A_c1 (M1-L801) and
KDM5A_c2 (DARID/PHD1, P13-S744 with L88-G353 (ARID/PHD1)replaced with a GGGG linker) and both KDM5A_c1 and KDM5A_c2
constructs lack the PHD2 and PHD3. We thus proposed that
KDM5A catalytic activity should not be affected by AMI derivatives
since the PHD3 domain in these proteins is absent. A MALDI-TOF
MS assay was used to measure the activity of H3K4me3 demethy-
lation in the presence of inhibitors (Table 2, Fig. 3C and D).
KDOAM25, a KDM5-selective JmjC-domain targeting small mole-
cule inhibitor,29 was used as a positive control. Interestingly, while
AMI was not an inhibitor of KDM5A activity, WAG-005 and 2a
inhibited demethylation activity of both KDM5A_c1 and
KDM5A_c2, at concentrations significantly below the AlphaScreen
displacement IC50 values with isolated PHD3 (Table 2, Supplemen-
tary Fig. S6).
This suggests that both WAG-005 and 2a can inhibit the cat-
alytic activity of KDM5A in a manner independent of PHD-finger
binding, presumably via binding to the JmjC domain. Further
kinetic analysis of KDM5A_c2 using formaldehyde dehydrogenase
(FDH) enzyme-coupled fluorescence assay indicated that 2a
Table 2
Inhibition of H3K4me3 demethylation activity of KDM5A using MALDI-TOF MS
assays. Dose-response inhibition assays were carried out with AMI derivatives or
KDOAM25 using different constructs of KDM5A. Average ± StdDev of n = 2 indepen-
dent assays.
Compounds IC50 (mM)
KDM5A_c1 KDM5A_c2
AMI >1000 >1000
WAG-005 82 ± 54 27 ± 2
1a >1000 >1000
2a 80 ± 29 37 ± 14
KDOAM25 1.7 ± 0.6 3.2 ± 3.1
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binding (a = 1.64 ± 0.85, Ki = 74 ± 28 mM) (Supplementary
Fig. S6A, B). No formaldehyde production was detected with 2a
in the absence of H3K4me3, suggesting that 2a is not a substrate
of KDM5A_c2, at least, under the assay conditions tested (Supple-
mentary Fig. S6C).2.4. Inhibition of H3K4me3-binding PHD-fingers of other JmjC-KDMs
by AMI derivatives
In order to test the specificity of the AMI derivatives for KDM5A,
cross-screens were performed using AlphaScreen binding assays
against the H3K4me3-binding PHD-fingers associated with other
JmjC-KDMs: KDM7A(KIAA1718), KDM7B(PHF8) and KDM7C
(PHF2) (Fig. 1A, Supplementary Figs. S4, S5).30 The PHD-fingers of
the KDM7 subfamily recognise H3K4me3.30,31 In the case ofTable 3
AlphaScreen IC50 values for displacement of H3K4me3-Bn from His-KDM7(PHD) by
AMI derivatives. Final concentrations of protein and H3K4me3-Bn were: 6.25 nM
KDM7A(PHD) and 25 nM peptide, 12.5 nM each for KDM7B(PHD), and 25 nM KDM7C
(PHD) and 6.25 nM peptide. Average ± StdDev (n  3 independent replicates) shown.
Compounds IC50 (mM)
KDM7A(PHD) KDM7B(PHD) KDM7C(PHD)
AMI 156 ± 12 252 ± 53 84 ± 14
WAG-003 2232 ± 790 307 ± 76 976 ± 146
WAG-005 50 ± 5 390 ± 158 740 ± 149
1a 333 ± 39 397 ± 77 158 ± 30
2a 86 ± 9 355 ± 39 579 ± 87
2b 108 ± 15 310 ± 78 598 ± 119
2c 104 ± 8 377 ± 76 501 ± 75
2d 98 ± 10 697 ± 154 682 ± 97
7a 102 ± 15 496 ± 181 1294 ± 280
7b 326 ± 14 286 ± 84 533 ± 99
8a 76 ± 14 240 ± 58 228 ± 66
8b 68 ± 13 242 ± 41 220 ± 40
10 534 ± 150 386 ± 41 359 ± 89
12 151 ± 17 221 ± 57 334 ± 45
H3(1–21)K4me3 1.9 ± 0.1 lM 1.7 ± 0.2 lM 2.7 ± 0.2 lM
Fig. 4. AlphaScreen binding assay for H3K4me3 and His-KDM7(PHD). Normalised dose–r
representative AMI derivatives.KDM7B, the PHD-finger primes the JmjC domain to catalyse
demethylation of nearby H3K9me2 (Fig. 1). Conversely, in KDM7A,
binding of H3K4me3 to the PHD-finger negatively affects the
demethylation activity of the JmjC domain at the H3K9me2 site,
likely due to the spacing constrains between the two domains.30
The majority of AMI derivatives weakly inhibited histone pep-
tide binding by the KDM7 PHD-fingers, albeit to varying degrees
(Table 3, Fig. 4). As observed with KDM5A(PHD3), there was little
consensus in terms of the preferred methylation and substitution
state of the amine group, with the trimethylammonium group con-
taining WAG-005 being most effective against KDM7A(PHD), the
triethylamino group containing compound 12 being most effective
against KDM7B(PHD), and the dimethylamino group containing 1a
being most effective against KDM7C(PHD). This was somewhat
surprising, given the 88% sequence similarity between the
KDM7 PHD-fingers. Additionally, there was a preference for the
3-(trimethylamine)-propoxy group in WAG-005 over the 2-
(trimethylamino)-ethoxy group in WAG-003 for binding to
KDM7A(PHD).
As observed for the KDM5A(PHD3), all AMI derivatives with o-
substitutions (7a) were less potent than those with p-substitutions
(2a); the 3,5-dimethoxy- and difluoro-containing compounds 8a
and 8b were more potent than their unsubstituted analogue 2a.
There was less agreement in the effect of the removal of the 3,5-
diiodo-groups, which reduced potency against KDM7A(PHD), and
improved potency against KDM7B(PHD) and KDM7C(PHD) (Table 3,
Fig. 4). Divergent trends are also observed in the heterocyclic
region (2b, 2c, and 2d); N-methylindole 2d was most potent
against KDM7A(PHD), benzofuran 2b was most potent against
the KDM7B(PHD), and the benzothiophene-containing 2c was
most potent against KDM7C(PHD). Overall, the results reveal that
AMI derivatives inhibit the KDM7 PHD-fingers, indicating that they
are likely not selective. WAG-003 and WAG-005 inhibited the
PHD-fingers of KDM7s at different potencies, with WAG-005 being
the most potent inhibitor of KDM7A(PHD).
2.5. Inhibition of binding and catalytic activity of KDM7A/B(PHD-JmjC)
by AMI derivatives
We next explored the effect of AMI and select derivatives
against the KDM7A/B JmjC domains. A dual-domain construct of
KDM7A/B(PHD-JmjC), consisting of a JmjC domain in addition to
the PHD-finger (Fig. 1B), was used to test for allosteric inhibition
through binding at the PHD-finger. The displacement IC50 profiles
for the dual domains were significantly different, and generally
lower, compared to that of the PHD finger-only constructs (Table 4).
KDM7A(PHD-JmjC) was particularly sensitive, with IC50 values of
WAG-005 and 2b at 16 mM and 5.6 mM, respectively.
The AMI derivatives were then tested for inhibition of KDM7A/
B-catalysed H3K9me2 demethylation using the MALDI-TOF MS
assay. H3(1–15)K9me2 and H3(1–5)K4me3K9me2 were used asesponse inhibition curves for the displacement of H3K4me3-Bn from KDM7A/B/C by
Table 4
Alphascreen IC50 values for displacement of H3K4me3-Bn from His-KDM7(PHD-JmjC) by AMI derivatives, and their inhibition of demethylation activity assessed by MALDI-TOF
MS. Displacement – AlphaScreen displacement data. Catalytic – H3K9me2 demethylation assay using MALDI-TOF MS. NI: No inhibition seen at 100 lM. Average ± StdDev (n = 3
for AlphaScreen).
Compounds IC50 (mM)
KDM7A (PHD-JmjC)
(Displacement)
KDM7A (PHD-JmjC)
(Catalytic)
KDM7B (PHD-JmjC)
(Displacement)
KDM7B (PHD-JmjC)
(Catalytic)
AMI 80 ± 26 83% (100 mM) – 22% (100 mM)
WAG-003 NI 17% (100 mM) NI 22% (100 mM)
WAG-005 16 ± 4 100% (100 mM) NI 33% (100 mM)
1a 295 ± 48 100% (100 mM) NI 95% (100 mM)
2a 149 ± 32 100% (100 mM) 120 ± 32 89% (100 mM)
2b 5.6 ± 1.5 100% (100 mM) 126 ± 34 32% (100 mM)
2d 88 ± 17 100% (100 mM) >300 24% (100 mM)
2990 B. Bhushan et al. / Bioorganic & Medicinal Chemistry 26 (2018) 2984–2991substrates for KDM7A(PHD-JmjC) and KDM7B(PHD-JmjC), respec-
tively. For KDM7A(PHD-JmjC), complete inhibition of K9me2
demethylation activity was observed for all AMI derivatives tested
(except WAG-003) at 100 mM. For KDM7B(PHD-JmjC), inhibition
was most pronounced for 1a (95%) and 2a (89%) whilst others
inhibited more weakly (Table 4).3. Discussion
AMI and its derivatives (WAG-003, WAG-005) have been iden-
tified as KDM5A(PHD3) inhibitors;26 they remain the only reported
inhibitors of PHD-fingers linked to JmjC-KDMs. To investigate the
tractability and selectivity of PHD-finger inhibition by this scaffold,
we generated a series of AMI derivatives and assessed their SAR
against KDM5A(PHD3) using an AlphaScreen-based binding assay.
While some of the AMI derivatives did indeed weakly displace the
H3K4me3 binding to KDM5A(PHD3), our results suggest their
potencies are an order of a magnitude lower than previously
reported. Small improvements in potency were obtained by modi-
fying the 3,5-substitutions on the aryl group. We hypothesised that
the tertiary amine in WAG-005 may be binding at the Ne-methy-
lated lysine binding pocket of KDM5A(PHD3). However, no clear
differences in binding potency was observed for derivatives with
differing amine alkylation states, in agreement with previous find-
ings.26 This is in contrast to histone H3 peptides, where higher
methylation states are clearly favoured (as shown for KDM5A in
Supplementary Fig. S2).
Interestingly, some AMI derivatives inhibited the catalytic
activity of the KDM5A and KDM7A/B JmjC domain, further indicat-
ing that they may act/bind via more than one mode. Kinetic anal-
ysis on 2a suggests that the binding is not competitive with respect
to histone H3K4me3 (Supplementary Fig. S6). However, further
biophysical analyses are needed to elucidate the precise modes
of action of the compounds.
The AMI derivatives were also found to be promiscuous binders
of the KDM7 PHD-fingers, and there was no clear trend in their
binding profiles across the PHD-fingers. It is important to note that
IC50 values are dependent on assay conditions. The differences
between the assay setup, such as the length of peptide and protein
constructs, can affect the absolute IC50 values (H3(1–21)K4me3
and KDM5A1542–1660 (PHD3) were used in our study compared to
H3(1–11 or 1–14)K4me3 and KDM5A1601-1660 (PHD3) used by
Wagner et al.26). It is possible that the increased binding affinity
of the longer peptide ligand to the longer reader domain scaffold
in our study may contribute to the higher IC50 values obtained.
Indeed, it is well reported that the binding and catalytic activities
change with different protein construct length and domain archi-
tecture,32 as demonstrated for the KDM5A and the KDM7 subfam-
ilies in this study. Thus, while isolated protein domains and
peptide fragments provide useful information, more work withfull-length proteins and nucleosomes are likely needed for robust
evaluation of small-molecule interactions.
The results presented here imply that AMI derivatives need fur-
ther optimisation to be useful as probes for the PHD-fingers. More
generally, they highlight the need for good quality PHD-finger inhi-
bitors. Despite the emerging importance of the PHD-fingers in driv-
ing epigenetic changes in diseases and compelling biology to
support PHD-finger as attractive cancer targets, the PHD-fingers
have been considered difficult targets for small molecule inhibi-
tion. Our results support this view, highlighting the challenges in
developing selective and potent small molecule inhibitors against
the PHD-fingers.
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